IHE Fact Sheet: iShares U.S. Pharmaceuticals ETF
Share
$107.05
close, Nov 18, 2026
Over the year to Nov 18, 2026, IHE returned +32.9% in total and charged 0.37% a year.
- 1-year total return
- +32.9%
- to Nov 18, 2026
- Expense ratio
- 0.37%
- a year
- Net assets
- $1.7bn
- on Nov 18, 2026
- Net flow, last 5 trading days
- +$22.1m
- daily basis to Nov 17, 2026
Growth of $10,000, 1 year
IHE $13,288 +32.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month+6.4%
3 months−0.8%
Year to date+27.3%
1 year+32.9%
3 years+94.3%
5 years+81.9%
Total return, distributions reinvested, each window to Nov 18, 2026.
Ten largest positions
HoldingWeight
ELI LILLY & COMPANY26.70%
JOHNSON & JOHNSON22.13%
VIATRIS4.88%
ZOETIS INC CLASS A4.83%
ROYALTY PHARMA PLC CLASS A4.81%
PFIZER4.35%
MERCK & CO INC4.12%
BRISTOL MYERS SQUIBB4.04%
JAZZ PHARMACEUTICALS PLC3.24%
ELANCO ANIMAL HEALTH2.68%
IHE top ten by weight, 81.8% of the fund, of its 52 equity positions, from the holdings published by its issuer for Nov 17, 2026.
Facts
Equity fund · Tracks the Dow Jones U.S. Select Pharmaceuticals Index · First traded May 5, 2006 · Benchmark Its own holdings, as of Nov 17, 2026